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Abstract Severe influenza is characterized by a cytokine
storm, and the influenza virus–cytokine–trypsin cycle is
one of the important mechanisms of viral multiplication
and multiple organ failure. The aim of this study was to
define the key cytokine(s) responsible for trypsin upregu-
lation. Mice were infected with influenza virus strain
A/Puerto Rico/8/34 (H1N1) or treated individually or with
a combination of interleukin-1b, interleukin-6, and tumor
necrosis factor a. The levels of these cytokines and trypsin
in the lungs were monitored. The neutralizing effects of
anti-IL-1b antibodies on cytokine and trypsin expression in
human A549 cells and lung inflammation in the infected
mice were examined. Infection induced interleukin-1b,
interleukin-6, tumor necrosis factor a, and ectopic trypsin
in mouse lungs in a dose- and time-dependent manner.
Intraperitoneal administration of interleukin-1b combined
with other cytokines tended to upregulate trypsin and
cytokine expression in the lungs, but the combination
without interleukin-1b did not induce trypsin. In contrast,
incubation of A549 cells with interleukin-1b alone induced
both cytokines and trypsin, and anti-interleukin-1b anti-
body treatment abrogated these effects. Administration of
the antibody in the infected mice reduced lung inflamma-
tion area. These findings suggest that IL-1b plays a key role
in trypsin upregulation and has a pathological role in
multiple organ failure.
Introduction
Multiple organ failure with vascular hyperpermeability is a
common cause of death in severe seasonal and highly
pathogenic influenza A virus infection. The condition is
usually associated with hypercytokinemia and severe
edema in the lung, heart, liver, kidneys and brain [1, 2]. In
our previous studies, we proposed the hypothesis of an
‘‘influenza–cytokine–trypsin’’ cycle as one of the key
mechanisms of vascular hyperpermeability and multiple
organ failure in severe influenza [3–6]. In the process of
influenza A virus entry into the cell, proteolytic conversion
of the viral envelope fusion glycoprotein hemagglutinin
(HA0) into HA1 and HA2 subunits by host cellular trypsin-
type proteases is a pre-requisite for membrane fusion
activity [5–10] because HA-processing protease is not
encoded in the viral genome. Once viral infection ensues,
ectopic pancreatic trypsin, which is one of the cellular HA-
processing proteases and is expressed in limited amounts in
various organs, such as the lungs, heart and brain, is
markedly upregulated through the induction of proinflam-
matory cytokines [3–6, 9]. The upregulated trypsin poten-
tiates viral multiplication in various organs, leading to
cellular dysfunction, vascular hyperpermeability and fluid
imbalance through proteinase-activated receptor-2 (PAR-2)
[4, 11–13] and tissue damage [14, 15] with the involvement
of matrix metalloproteases (MMPs) [10, 16, 17]. Trypsin is
also reported to be crucial for infectivity of other viruses,
such as rotaviruses, members of the family Reoviridae, and
coronaviruses, members of the family Coronaviridae
[18, 19], in addition to influenza A virus, a member of the
family Orthomyxoviridae, and Sendai virus and Newcastle
disease virus, members of the family Paramyxoviridae.
Pro-inflammatory cytokines, such as interleukin-1b (IL-
1b), interleukin-6 (IL-6), and tumor necrosis factor a
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(TNF-a), are increased in the infected organs and blood,
and such hypercytokinemia is considered a host defense
response to influenza virus infection [20]. The presence of
high levels of pro-inflammatory cytokines, however,
impairs energy metabolism in mitochondria, leading to
cellular dysfunction and organ failure [21]. Although we
reported in our previous in vivo and in vitro studies
[3, 4, 21] that pro-inflammatory cytokine(s) can trigger
trypsin upregulation through the influenza–cytokine–tryp-
sin cycle, it is still not clear whether there is a key cytokine
that affects trypsin upregulation, followed by the cascades
of multiple organ failure in severe influenza.
The effects of challenges with individual and multiple
pro-inflammatory cytokines on the inflammatory responses
in various organs have been reported not only in mice and
rats [22–25] but also in various cell lines [26–31]. These
studies highlighted the interactions between IL-1b, IL-6
and TNF-a, which contribute to disease progression.
However, little or no information is available on cytokine
cross-talk in trypsin upregulation.
The aim of the present study was to determine the
presence of pro-inflammatory cytokine(s) cross-talk and its
effects on trypsin upregulation, particularly in the lungs,
which are the initial site of influenza virus replication. In
addition to animal studies, we also used A549 cells, a
human type II lung epithelial cell line, to confirm the
results of the animal experiments. The A549 cell line is
suitable for the experiments because these cells constitu-




Specific- pathogen-free 5-week-old C5B7BL/6J female
mice were purchased from SLC (Saitama, Japan). The mice
were treated according to the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, 1996),
and the study was approved by the Animal Care Committee
of Tokushima University. Influenza virus A/Puerto Rico/8/
34 (H1N1) (PR8) was kindly provided by The Research
Foundation for Microbial Diseases of Osaka University
(Kagawa, Japan). Under ketamine and xylazine anesthesia,
1 to 40 plaque-forming units (pfu) of PR8 in 15 lL of
saline or saline alone as non-infection control were instilled
intranasally in mice. In the cytokine administration
experiments, mice were treated by intraperitoneal injection
of 100 lL of a single cytokine or a combination of
cytokines twice a day for three days. The cytokines used
for treatment were mouse recombinant IL-1b, IL-6, and
TNF-a (R&D Systems, Minneapolis, MN) at a dose of
40 lg/kg per day. The dose was within the range of
cytokines found in the lungs after 25 pfu of PR8 infection
and was also within the dose recommended in a previous
study [22]. Mice were monitored daily for body weight and
survival rate and were euthanized at 0, 3, 4, 6, and 8 days
postinfection, and the lungs were extracted to measure the
levels cytokines and trypsin.
To assess the pathological role of IL-1b in multiple
organ failure, 100 lL of anti-mouse IL-1b goat polyclonal
antibodies (R&D Systems) for neutralization, purified
mouse IgG from normal mice (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) at 1 mg/mL, or saline as the
vehicle was administered intraperitoneally to mice. After
treatment for 1 hour, 25 pfu of PR8 in 15 lL of saline or
saline alone was instilled intranasally. Mice were eutha-
nized at day 7 postinfection, and lungs were processed for
histopathological evaluation.
Histological analysis
The lungs were perfused with 30-40 mL of saline through
the right atrium of the heart, fixed with 10 % buffered
formalin, pH 7.2, isolated, and embedded in paraffin. The
paraffin block was cross-sectioned with 5 lm thickness
using a microtome (Leica). Hematoxylin and eosin (HE)
staining was done subsequently. Images were acquired
with a microscope (BZ-X710; Keyence Corporation,
Osaka, Japan). To analyze the image of a whole lung,
partial lung images were combined using BZ-X analyzer
software (Keyence), and the percentage of the whole lung
composed of hypercellular areas associated with infiltration
of inflammatory cells was determined using BZ-X analyzer
software as described previously [33, 34].
Cell culture
Human alveolar type II epithelial cell carcinoma (A549)
cells were obtained from ATCC. The cells (3 9 105/well)
were cultured at 37 C under 5 % CO2 in Dulbecco‘s
modified Eagle medium (DMEM) containing 10 % fetal
bovine serum and 50 lg of gentamycin per ml. Cells were
passaged every 2 days. After 24 hours of starvation, the
cells were treated with 10 ng of human recombinant IL-1b
per ml for 1 hour, washed three times with PBS(-), and then
cultured in fresh serum-free medium for 8 or 24 hours. At
the indicated time points, the cells and medium were
collected.
To assess the role of IL-1b in the influenza–cytokine–
trypsin cycle in A549 cells, human recombinant IL-1b at
10 ng/mL in serum-free medium was pre-treated with
600 ng of anti-human IL-1b monoclonal antibody (R&D
Systems) per ml for neutralization, or with PBS(-) at 37 C
for 30 minutes. These reaction mixtures were added to
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A549 cells, and the cells were cultured for 1 hour for
stimulation. The cells were then washed three times with
PBS(-) and cultured in fresh serum-free medium for an
additional 8 hours, and the mRNA levels of trypsin, IL-1b,
IL-6, and TNF-a were measured.
Enzyme-linked immunosorbent assay (ELISA)
Freshly isolated lungs were homogenized with 10 volumes
of PBS(-) and centrifuged at 11,1009g for 20 minutes at
4 C, and the supernatants were isolated. The lung extracts
and media from A549 cell culture were subjected to ELISA
analysis. The levels of IL-6, TNF-a and IL-1b, and trypsin
were measured using ELISA kits (R&D Systems) accord-
ing to the respective protocol provided by the
manufacturer.
Extraction of total RNA and real-time reverse
transcription polymerase chain reaction (RT-PCR)
analysis
Total RNA from A549 cells was isolated using an RNeasy
Mini Kit (QIAGEN, Hilden, Germany) using the protocol
supplied by the manufacturer. The cDNAs were synthesized
using oligonucleotide primers and SuperScript III RT (Gibco
BRL, Grand Island, NY). Real-time RT-PCR was used to
measure expression of the human b-actin gene (accession
number NM_001101.3), trypsin PRSS1 (accession number
NM_002769.4), PRSS2 (accession number NM_002770.3),
PRSS3 (accession number NM_002771.3), IL-1b (accession
number NM_000576.2), IL-6 (accession number NM_000
600.3), and TNF-a (accession number NM_000594.3).





C-3’ (reverse); PRSS2, 5’-CCCCTTTGATGATGATGAC-
3’ (forward) and 5’-AACTGTTCATTCCCCTCC-3’ (re-
verse); PRSS3, 5’-AGCGAACAGTGGGTGGTATC-3’
(forward) and 5’-GGCAGGTGAGGAGAGTTTGA -3’
(reverse); IL-1b, 5’-AAATACCTGTGGCCTTGGGC-3’
(forward) and 5’-TTTGGGATCTACACTCTCCAGCT-3’
(reverse); IL-6, 5’-GTAGCCGCCCCACACAGA-3’ (for-




A SYBR Green PCR kit (Roche Diagnostics, Man-
nheim, Germany) and an ABI 7300 system (Applied
Biosystems, Foster City, CA) were used to quantify these
genes. The reaction conditions were set at 95 C for 10
minutes, followed by 40 cycles of 30-second denaturation
at 95 C, 30-second annealing at 58 C (for b-actin, PRSS1
and PRSS3), 55 C (for PRSS2) or 60 C (for IL-1b, IL-6,
and TNF-a) and 50-second extension at 72 C. The relative
units were calculated from a standard curve and normalized
to that of human b-actin.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) of
at least three replicates, unless stated otherwise. Differ-
ences between groups were examined for statistical sig-
nificance by Student’s t-test. A P-value less than 0.05 was
considered statistically significant.
Results
Modes of upregulation of pro-inflammatory
cytokines and ectopic trypsin in lungs by influenza
A virus infection
Mice were infected with influenza A virus PR8 to study the
mode of upregulation pro-inflammatory cytokines and
ectopic trypsin in the lungs in the early phase of infection.
Based on the survival rates and changes in body weight at
various doses of PR8 infection (Fig. 1A), we chose 25 pfu as
the infection dose for subsequent experiments designed to
measure the changes in cytokines and trypsin in the lungs.
IL-6 andTNF-a levelswere increased significantly at day 3
postinfection and then gradually decreased afterwards.
Meanwhile, the levels of IL-1b and trypsin were also
increased significantly at day 3 postinfection, but the levels
continued to be persistently high until day 8, although the high
levels of IL-1b returned rapidly to the baseline (before
infection) at day 8 (Fig. 1B). Interestingly, infected mice,
particularly those infectedwith 25 and 40pfu, showed signs of
sickness (e.g., inactivity, ruffled fur, labored respiration, and
body weight loss) after infection for 3 days, coinciding with
the rise in pro-inflammatory cytokines and trypsin levels.
Figure 2 shows the dose-response profile of the effect of
PR8 virus infection on the upregulation of trypsin, IL-1b,
IL-6, and TNF-a in the lungs at day 3 post-infection. The
results indicate that upregulation of trypsin, IL-1b, IL-6,
and TNF-a correlates closely with the viral dosage.
Exogenously injected IL-1b alone or in combination
with other cytokines induces similar morbidity
characteristics and upregulates cytokines
and trypsin in the lungs in the same manner
as influenza A virus infection
To clarify the role of cytokines in the host cellular
responses to infection, we analyzed the effect of
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intraperitoneal administration of IL-1b alone or IL-1b
combined with IL-6 and/or TNF-a on the levels of ectopic
trypsin and pro-inflammatory cytokines at day 3 post-
treatment and measured changes in body weight. Animals
treated with IL-1b alone or IL-1b combined with IL-6 and/
or TNF-a became sick and lost weight in a manner similar
to that observed in mice infected with 25 pfu of PR8.
However, mice treated with IL-6 and/or TNF-a did not
show any detectable symptoms or visible body weight loss
(Fig. 3A). These findings suggest that IL-1b seems to play
Fig. 1 Effects of PR8 infection on body weight and survival rates
(A) and the levels of pro-inflammatory cytokines and ectopic trypsin
in the lungs (B). Anesthetized C5B7BL/6 J mice were infected
intranasally with 5, 25, and 40 pfu of influenza virus PR8 or instilled
saline as a control. Mice were sacrificed at days 0, 3, 4, 6, and 8 after
infection. The levels of trypsin, IL-1b, IL-6, and TNF-a in the lungs
were analyzed by ELISA. Data are the mean ± SD for 10 mice per
group. *, P\ 0.05 vs. the uninfected group (saline) by Student’s t-test
Fig. 2 Dose-response profiling
of PR8 virus on the upregulation
of trypsin, IL-1b, IL-6, and
TNF-a in the lungs. Each group
(n = 3) received different doses
of PR8. The levels of trypsin,
IL-1b, IL-6, and TNF-a in the
infected lungs were measured.
Data are the mean ± SD. *,
P\ 0.05 vs. the uninfected
group (saline) by Student’s t-
test
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an important role in signal cascades in the pathogenesis of
severe influenza virus infection.
Under the same experimental conditions, we further
analyzed the levels of ectopic trypsin and pro-inflammatory
cytokines in the lungs at day 3 post-treatment (Fig. 3B).
Trypsin levels were not significantly increased following
the administration of each cytokine but tended to increase
following administration of IL-1b combined with IL-6 and/
or TNF-a. In particular, the trypsin level induced by the
combination of IL-1b plus IL-6 was significantly higher
than that induced by IL-1b alone or saline. The combina-
tion of cytokines without IL-1b did not induce trypsin in
the lungs. These results suggest that IL-1b is indispensable
for trypsin upregulation and that IL-6 and/or TNF-a plays a
co-stimulatory role in the effects of IL-1b.
IL-1b in the lungs increased significantly after admin-
istration of IL-1b or various cytokine combinations.
Although IL-6 was not induced by IL-1b alone, it was
induced significantly by IL-6, TNF-a and cytokine com-
binations including IL-1b.
IL-1b-treated human alveolar A549 cells upregulate
trypsin and increase pro-inflammatory cytokine
secretion in a time-dependent manner
To confirm the role of IL-b in trypsin upregulation in lung
epithelial cells, the site of initial virus infection, human
alveolar A549 cells were treated with 10 ng of IL-b per ml,
and the expression levels of trypsin in the cells and the levels
of secreted IL-1b, IL-6 and TNF-a in the medium were
analyzed. The earliest response to the challenge was IL-1b
secretion, detected at 2 hours in the medium, followed by
secretion of IL-6 and TNF-a at 4 and 6 hours, respectively,
with significant upregulation of trypsin 1 (PRSS1) mRNA,
detected at 8 hours in the cells in the presence of IL-1b, IL-6
and TNF-a in the medium (Fig. 4). The levels of these
cytokines and trypsin 1 increased continuously in a time-
dependent manner during the 8-hour experiment. The other
isoforms of human major trypsin mRNAs, such as PRSS2
and PRSS3, were also upregulated after IL-1b treatment in a
manner similar to PRSS1, with peaks at 8 hours, and then
Fig. 3 Effects of intraperitoneal injection of IL-1b and other
cytokines on body weight and the levels of pro-inflammatory
cytokines and trypsin in the lungs. IL-1b alone and IL-1b combined
with other cytokines were injected intraperitoneally twice a day for
three days, and the change in body weight was monitored (A). Data
are the mean ± SD (n = 3), except data for PR8 (n = 10). The levels
of pro-inflammatory cytokines and trypsin in the lungs at day 3 after
infection with PR8 (25 pfu) were analyzed by ELISA (B). Data are
the mean ± SD (n = 3). *, P\ 0.05 vs. saline; 1, P\ 0.05 vs. the
IL-1b-injected group by Student’s t-test. ND, not detectable
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gradually declined within 24 hours (Fig. 5). These findings
indicate that IL-1b stimulates these trypsin isoforms gene
expression equally in the lungs.
Suppression of IL-1b by neutralizing monoclonal
antibody markedly reduces trypsin, IL-1b, IL-6
and TNF-a upregulation
An IL-1b neutralization experiment was performed to add
further support for the role of IL-1b in the upregulation of
trypsin and pro-inflammatory cytokines in A549 cells
(Fig. 6). IL-1b at 10 ng/mL was initially reacted with or
without 600 ng of anti-human IL-1b monoclonal antibody
per ml for neutralization in serum-free medium for 30
minutes. These reaction mixtures were then added to A549
cells, and the cells were stimulated for 1 hour, washed with
PBS (-), and cultured for an additional 8 hours in serum-
free medium. After incubation, trypsin, IL-1b, IL-6 and
TNF-a mRNA levels in the cells and secreted IL-1b and
IL-6 levels in the medium were analyzed. Anti-IL-1b
monoclonal antibody effectively abrogated the upregula-
tion of trypsin, IL-1b, IL-6, and TNF-a mRNAs in the cells
and reduced the levels to those seen at baseline. Further-
more, IL-1b neutralization also prevented the rise in
secreted IL-1b and IL-6 protein levels in the medium.
Administration of anti-IL-1b neutralizing antibody
significantly restrains development of inflammation
in the lungs of mice infected with influenza A virus
To verify the role of IL-1b in the influenza–cytokine–trypsin
cycle andmultiple organ failure in infectedmice, anti-mouse
IL-1b neutralizing polyclonal antibodies were administrated
intraperitoneally before infection and pathohistological
Fig. 4 Kinetics of upregulation
of trypsin, IL-1b, IL-6 and
TNF-a in cultured A549 cells
after treatment with human
recombinant IL-1b. A549 cells
were primed with 10 ng of
recombinant human IL-1b per
mL for 1 hour, washed with
PBS(-), and then incubated in
fresh serum-free medium
containing IL-1b for 0 to 8
hours. Trypsin mRNA levels in
the cell lysates and the levels of
IL-1b, IL-6, and TNF-a in the
culture medium were analyzed.
Data are the mean ± SD
(n = 3). *, P\ 0.05 vs. the
untreated group; #, P\ 0.05 vs.
0 hour by Student’s t-test
Fig. 5 Gene upregulation of trypsin isoforms in A549 cells treated
with human recombinant IL-1b. After 1 hour of incubation with 10 ng
of IL-1b per mL at 37 C, cells were collected to measure mRNA
levels of human trypsin (PRSS) 1, 2, and 3 at various time points
within 24 hours. #, P\ 0.05 vs. 0 hour (before IL-1b addition) by
Student’s t-test
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analysis in the lungs was conducted at day 7 postinfection,
the time point of severe lung inflammation. In the lungs of
infected mice treated with saline or mouse IgG as a negative
control, inflammatory cells infiltrated and accumulated not
only in bronchial regions and alveolar walls but also arterial
and venous areas, resulting in abnormal thickening, resulting
in strong staining with hematoxylin (Fig. 7A). Some lungs
even exhibited damaged alveolar structure. In the lungs of
infectedmice treatedwith anti-IL-1b neutralizing polyclonal
antibodies, however, the distribution and accumulation of
inflammatory cells in the lungs were restricted. The hyper-
cellular areaswith inflammatory cell infiltration shown in red
and the hypocellular areas shown in green were then quan-
tified in the whole lung area (Fig. 7B). Histological quan-
tification of the hypercellular area showed that anti-IL-1b
neutralizing antibody treatment significantly suppressed the
development of inflammatory cell aggregation when com-
pared to the saline and control mouse IgG groups.
Discussion
In the present study, we made several new observations: 1)
among the pro-inflammatory cytokines IL-1b, IL-6 and
TNF-a, which are induced in the early phase of PR8
infection, IL-1b plays a key role in trypsin upregulation in
mouse lungs and human alveolar A549 cells. 2) IL-1b in
combination with IL-6 and/or TNF-a effectively upregu-
lated trypsin in mouse lungs, but the combination of
cytokines without IL-1b did not. 3) IL-1b upregulated
trypsin mRNAs (PRSS1, PRSS2, and PRSS3) equally in
A549 cells in the presence of IL-1b, IL-6 and TNF-a. 4)
Anti-IL-1b antibody neutralized IL-1b and efficiently
suppressed the upregulation of pro-inflammatory cytokines
and trypsin in A549 cells and also suppressed the devel-
opment of inflammatory cell aggregation in the lungs of
infected mice.
We reported previously that influenza A virus infection
resulted in significant increases the levels of in IL-1b, IL-6,
TNF-a, the viral hemagglutinin processing protease ectopic
trypsin, and viral replication in the lungs of the host animal
[3]. Upregulation of trypsin induces [Ca2?]i mobilization
via activation of PAR-2, followed by the loss of the
intracellular tight junction protein zonula occludens-1,
resulting in vascular hyperpermeability and multiple organ
failure [3, 4, 6]. Furthermore, inhibitors of nuclear factor-
kappa B (NF-jB) and activator protein 1 (AP-1) effectively
suppress the upregulation of proinflammatory cytokines
and ectopic trypsin and improve the survival rate of
infected mice [3]. Based on these results, we proposed the
Fig. 6 Suppressive effects of an anti-IL-1b-neutralizing monoclonal
antibody on IL-1b-induced upregulation of trypsin and pro-inflam-
matory cytokines in A549 cells. IL-1b (10 ng/mL) in serum-free
medium was reacted with or without anti-IL-1b monoclonal antibody
(600 ng/mL) for 30 minutes at 37 C. These reaction mixtures were
added to A549 cells, and the cells were stimulated for 1 hour by
incubation at 37 C. The cells were then washed with PBS(-) and
incubated for an additional 8 hours with fresh serum-free medium.
After incubation, the mRNA levels of trypsin 1, IL-1b, IL-6, and
TNF-a in the cells and the levels of IL-1b and IL-6 in medium were
analyzed. *, P\ 0.05 vs. the untreated group; #, P\ 0.05 vs. the IL-
1b-treated group by Student’s t-test
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influenza virus–cytokine–trypsin cycle hypothesis as one of
the mechanisms of trypsin upregulation and vascular dys-
function in multiple organ failure with cytokine storm in
severe influenza.
In this study, our interest was to identify major pro-
inflammatory cytokines that can switch on trypsin upreg-
ulation in severe influenza A virus infection. We identified
IL-1b as a key cytokine capable of inducing IL-1b, IL-6,
TNF-a, and trypsin in mouse lungs and human alveolar
A549 cells in the early phase of infection. We used four
experiments to provide support for this result. First, we
found that intraperitoneal injection of a mixture of pro-
inflammatory cytokines (IL-1b, IL-6 and TNF-a) upregu-
lated ectopic trypsin in the lungs, while a cytokine mixture
that lacked IL-1b did not (Fig. 3B). Second, incubation of
A549 cells in the presence of IL-1b stimulated IL-1b
secretion initially, followed by secretion of IL-6 and TNF-
a, and finally upregulated trypsin mRNAs in the presence
of IL-1b, IL-6 and TNF-a in the culture medium (Fig. 4
and 5). Third, neutralization of IL-1b by monoclonal
antibody against IL-1b almost completely suppressed such
inductions in vitro (Fig. 6). Lastly, intraperitoneal admin-
istration of anti-IL-1b neutralizing polyclonal antibodies
efficiently suppressed the development of inflammatory
cell aggregation in the lungs of an infected mouse (Fig. 7).
The effects of cytokine synergism have been reported in
various host cellular responses. Synergistic effects of IL-
1b, IL-6 and TNF-a on inflammatory and stress mediators
[22] and IL-1b and IL-17 on chronic lung inflammation
after viral infection [23] have been reported. In particular,
the interaction between IL-1b and IL-6 in many types of
inflammation [24–26] and the mechanisms of synergism
[27–29] have been studied extensively. Our results add
support to these findings and confirm that IL-1b upregu-
lates trypsin in the presence of IL-6 and/or TNF-a.
We reported previously that inhibitors of NF-jB and
AP-1 effectively suppress the upregulation of proinflam-
matory cytokines, ectopic trypsin, viral replication, and
endothelial dysfunction, resulting in a significant
improvement in the survival of infected mice [3]. These
Fig. 7 Administration of anti-IL-1b neutralizing polyclonal antibod-
ies restrains development of inflammation in the lungs of mice
infected with influenza A virus. Groups of mice received 100 lL of
anti-mouse IL-1b neutralizing polyclonal antibodies, mouse IgG at
1 mg/mL, or saline prior to infection. After administration for 1 hour,
25 pfu of PR8 in 15 lL of saline or saline alone was instilled
intranasally. At day 7 postinfection, mice were sacrificed and isolated
lungs were prepared for hematoxylin and eosin staining. Images of
histological analysis were acquired with a microscope (BZ-X710)
with 2 9 magnification (A). The hypercellular areas shown in red and
the hypocellular areas shown in green were quantified in the lung.
The percentage of the whole lung occupied by hypercellular areas was
determined using BZ-X analyzer software (B). Scale bar, 300 lm. *,
P\ 0.05 by Student’s t-test
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transcription factors are activated by IL-1b signaling
through mitogen-activated protein kinases (MAPKs) and
the NF-jB pathway, as shown in previous studies [35–38].
These previous studies, including ours [3], support the
present findings of the role of IL-1b in trypsin upregulation
in combination with IL-6 and/or TNF-a, and also on the
role of trypsin in the induction of various signal trans-
ductions in multiple organ failure. The pronounced sup-
pressive effects of anti-IL-1b antibody on these effects also
confirmed the crucial role of IL-1b.
The present study indicates a key role for IL-1b in
trypsin upregulation in the early phase of influenza A virus
infection in mouse lung. Figure 8 illustrates our hypothesis
on the role of IL-1b in the influenza virus–cytokine–trypsin
cycle and its synergistic interaction with IL-6 and/or TNF-
a as indicated by arrow directions based on our results and
the data reported [23–26]. Influenza A virus infection
upregulates the proinflammatory cytokine IL-1b, followed
by IL-6 and TNF-a, with synergistic interaction. Since
upregulated trypsin efficiently converts pro-MMPs to
active MMPs [16, 39], induction of trypsin and active
MMPs synergistically degrades the vascular basement
membrane and extracellular matrix, resulting in tissue
damage, edema, and multiple organ failure. In addition, the
upregulated trypsin in turn provokes cytokine release [40],
cellular fluid imbalance, and loss of the intracellular tight
junction protein zonula occludens-1 [3] via PAR-2 acti-
vation. These trypsin-based cascades result in vascular
hyperpermeability and multiple organ failure in severe
influenza.
Many studies have provided evidence for the therapeutic
effects of controlling the balance of IL-1b within certain
levels in various diseases by blocking IL-1b receptor or
neutralization antibodies [23, 41–47]. Our in vivo experi-
ment using anti-IL-1b neutralizing antibodies also
demonstrated a similar outcome. In addition, our findings
regarding the hypothesis illustrated in Figure 8 highlight
the important effect of restraining IL-1b-stimulation to
avoid trypsin-mediated disease aggravation. Moreover,
further studies focusing on IL-1b directed synergic effects
of pro-inflammatory cytokines on trypsin upregulation are
needed to strengthen our proposed hypothesis. In addition,
several hemagglutinin- processing proteases in human
airway epithelium other than trypsin, such as TMPRSS2
and HAT, play roles in influenza virus multiplication [48].
We cannot deny the possibility that upregulation of IL-1b
and other pro-inflammatory cytokines by infection also
induces these processing proteases. Therefore, further
studies on the effects of inflammatory cytokines, including
IL-1b on these hemagglutinin processing proteases are
needed to understand the pathogenesis of multiple organ
failure in severe influenza.
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